ASCO Preview: Bristol PD-1 Data Spur Hopes For Double Immunotherapy
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Immune checkpoint antibodies feature prominently in American Society of Clinical Oncology annual meeting program, showing promise in a range of cancers. Bristol showcases data for Yervoy in combination with its anti-PD-1 nivolumab in melanoma, while Roche unveils extensive early results for its anti-PD-L1 MPDL3280A.